MLYS
Mineralys Therapeutics, Inc.
Latest Form 4:Sale$193KbyWarren Eric (Chief Commercial Officer) · filed Aug 25, 2026
Mineralys Therapeutics, Inc. (MLYS) has 56 SEC Form 4 filings (161 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Aug 25, 2026.
The most active filer is Chief Medical Officer Rodman David Malcom with 34 filings. Insiders have net sold $2.3M over the trailing 6 months. The largest single insider purchase in this window was $7.4M by Director RA CAPITAL MANAGEMENT, L.P. on Mar 27, 2026.
- Industry:Biotechnology
- CEO:Jon Congleton
- Employees:51
- HQ:Radnor, PA, US
- IPO:2023-02-10
Insider Buying
$53.8M
reported purchases (SEC code P)
Insider Selling
$84.7M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Market Cap
$2.1B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Commercial Officer | Sale | 7,437 | $193K | Aug 25 | SEC ↗ | |
| Chief Medical Officer | Sale | 2,170 | $59K | Aug 12 | SEC ↗ | |
| Chief Commercial Officer | Sale | 7,438 | $200K | Jul 23 | SEC ↗ | |
| Chief Medical Officer | Sale | 416 | $11K | Jul 21 | SEC ↗ | |
| Chief Executive Officer | Sale | 10,700 | $291K | Jul 16 | SEC ↗ | |
| Chief Medical Officer | Sale | 14,058 | $388K | Jul 16 | SEC ↗ | |
| Chief Medical Officer | Sale | 6,349 | $169K | Jul 16 | SEC ↗ | |
| Chief Medical Officer | Sale | 2,171 | $66K | Jul 10 | SEC ↗ | |
| Chief Executive Officer | Sale | 75,000 | $2.0M | Jun 30 | SEC ↗ | |
Warren EricFirst filing | Chief Commercial Officer | Sale | 104,124 | $2.7M | Jun 30 | SEC ↗ |
| Chief Medical Officer | Sale | 9,890 | $235K | Jun 18 | SEC ↗ | |
| Chief Medical Officer | Sale | 4,584 | $115K | Jun 18 | SEC ↗ | |
| Director | Sale | 3,000 | $75K | Jun 18 | SEC ↗ | |
| Chief Medical Officer | Sale | 2,170 | $54K | Jun 12 | SEC ↗ | |
| Chief Medical Officer | Sale | 6,349 | $152K | Jun 12 | SEC ↗ | |
| Chief Medical Officer | Sale | 417 | $11K | May 19 | SEC ↗ | |
| Chief Medical Officer | Sale | 2,171 | $65K | May 14 | SEC ↗ | |
| Chief Medical Officer | Sale | 6,348 | $186K | May 14 | SEC ↗ | |
| Chief Medical Officer | Sale | 14,056 | $402K | May 14 | SEC ↗ | |
| Chief Medical Officer | Sale | 416 | $13K | Apr 21 | SEC ↗ | |
| Chief Medical Officer | Sale | 14,058 | $373K | Apr 15 | SEC ↗ | |
| Chief Medical Officer | Sale | 6,348 | $176K | Apr 15 | SEC ↗ | |
| Chief Executive Officer | Sale | 15,730 | $422K | Apr 15 | SEC ↗ | |
| Chief Medical Officer | Sale | 2,170 | $59K | Apr 13 | SEC ↗ | |
| Chief Executive Officer | Sale | 75,000 | $2.0M | Apr 2 | SEC ↗ | |
Karydas DaphneFirst in 5 months | Director | Sale | 3,000 | $75K | Apr 2 | SEC ↗ |
| Director | Purchase | 310,700 | $7.4M | Mar 31 | SEC ↗ | |
| Director | Purchase | 58,300 | $1.4M | Mar 31 | SEC ↗ | |
| Chief Medical Officer | Sale | 417 | $11K | Mar 17 | SEC ↗ | |
| Chief Medical Officer | Sale | 6,348 | $174K | Mar 16 | SEC ↗ | |
| Chief Medical Officer | Sale | 14,058 | $369K | Mar 16 | SEC ↗ | |
| Chief Medical Officer | Sale | 2,171 | $58K | Mar 10 | SEC ↗ | |
| Chief Medical Officer | Sale | 417 | $12K | Feb 17 | SEC ↗ | |
| Chief Medical Officer | Sale | 6,349 | $184K | Feb 13 | SEC ↗ | |
| Chief Medical Officer | Sale | 14,055 | $386K | Feb 13 | SEC ↗ | |
| Chief Medical Officer | Sale | 2,171 | $66K | Feb 11 | SEC ↗ | |
| Chief Medical Officer | Sale | 416 | $13K | Jan 20 | SEC ↗ | |
| Chief Medical Officer | Sale | 7,709 | $252K | Jan 15 | SEC ↗ | |
| Chief Medical Officer | Sale | 11,367 | $371K | Jan 15 | SEC ↗ | |
| Chief Medical Officer | Sale | 2,170 | $72K | Jan 13 | SEC ↗ | |
| Chief Medical Officer | Sale | 6,348 | $205K | Jan 13 | SEC ↗ | |
| Chief Executive Officer | Sale | 16,236 | $530K | Jan 13 | SEC ↗ | |
| CFO and Secretary | Sale | 10,758 | $346K | Jan 13 | SEC ↗ | |
| Chief Medical Officer | Sale | 70,037 | $2.5M | Jan 6 | SEC ↗ | |
| Chief Medical Officer | Sale | 192,715 | $6.7M | Jan 6 | SEC ↗ | |
Slingsby Brian TaylorFirst filing | Director, 10% Owner | Sale | 1,000,000 | $43.4M | Nov 21 | SEC ↗ |
| CFO and Secretary | Sale | 119,524 | $5.4M | Nov 13 | SEC ↗ | |
Gold Alexander MFirst filing | Director | Sale | 15,000 | $660K | Nov 13 | SEC ↗ |
Gold Alexander MFirst filing | Director | Sale | 6,933 | $324K | Nov 13 | SEC ↗ |
Gold Alexander MFirst filing | Director | Sale | 12,742 | $593K | Nov 13 | SEC ↗ |
| Chief Executive Officer | Sale | 200,000 | $9.1M | Nov 13 | SEC ↗ | |
Karydas DaphneFirst filing | Director | Sale | 15,000 | $690K | Nov 13 | SEC ↗ |
Levy Adam ScottFirst filing | CFO and Secretary | Sale | 10,758 | $452K | Oct 15 | SEC ↗ |
Congleton JonFirst filing | Chief Executive Officer | Sale | 15,100 | $644K | Oct 15 | SEC ↗ |
| Chief Medical Officer | Sale | 10,369 | $446K | Oct 15 | SEC ↗ | |
Rodman David MalcomFirst filing | Chief Medical Officer | Sale | 11,367 | $409K | Sep 16 | SEC ↗ |
RA CAPITAL MANAGEMENT, L.P.First filing | Director | Purchase | 1,176,470 | $30.0M | Sep 8 | SEC ↗ |
AKKARAJU SRINIVASFirst filing | Director | Purchase | 588,235 | $15.0M | Sep 8 | SEC ↗ |
Related companies
Mineralys Therapeutics, Inc. is in the Healthcare sector.